88720-62-1

Usage

Uses

Used in Pharmaceutical Industry:
Glycine, N-(3-pyridinylmethyl)(9CI) is used as an intermediate in the synthesis of organic compounds for the development of pharmaceuticals. Its unique structure allows it to be a valuable building block for the creation of amino acid derivatives with specific properties and functions.
Used in Chemical Research and Development:
In the chemical industry, Glycine, N-(3-pyridinylmethyl)(9CI) serves as a key component in research and development efforts to create new compounds. Its potential applications extend to various areas, including the design of novel materials and the enhancement of existing chemical processes.
Used in Drug Development:
Glycine, N-(3-pyridinylmethyl)(9CI) is being studied for its potential use in drug development due to its biological activity. This makes it a promising candidate for the creation of new therapeutic agents that could address a range of health conditions and diseases.

InChI:InChI=1/C8H10N2O2/c11-8(12)6-10-5-7-2-1-3-9-4-7/h1-4,10H,5-6H2,(H,11,12)

Upstream product

• 3099-31-8 nicotinyl chloride 

Relevant academic research and scientific papers

Synthesis and antitumor activity of novel pyridinium fullerene derivatives

Purpose: We have previously reported that some cationic fullerene derivatives exhibited anticancer activity, and they are expected to be a potential lead compound for an anti-drug resistant cancer agent. However, they are bis-adducts and a mixture of multiple regioisomers, which cannot be readily separated due to the variability of substituent positions on the fullerene cage. To overcome this issue, we evaluated the antiproliferative activities of a set of mono-adduct derivatives and examined their structure-activity relationship. In addition, the in vivo antitumor activity of selected derivatives was also examined. Methods: Nineteen pyridinium fullerene derivatives were newly designed and synthesized in this study. Their antiproliferative activities were evaluated using several cancer cell lines including drug-resistant cells. Furthermore, in vivo antitumor activity of several derivatives was investigated in mouse xenograft model of human lung cancer. Results: The derivatives inhibited the proliferation of cancer cell lines, including cisplatin-resistant cells and doxorubicin-resistant cells. It was also shown that compound 10 (10 μM), 13 (10 μM) and cis-14 (10 μM) induced the intracellular oxidative stress. In addition, compound 13 (20 mg/kg) and cis-14 (15 mg/kg) significantly exhibited antitumor activity in mouse xenograft model of human lung cancer. Conclusion: We synthesized a novel set of mono-adduct fullerene derivatives functionalized with pyridinium groups and found that most of them show potent antiproliferative activities against cancer cell lines and some of them show significant antitumor activities in vivo. We propose that these fullerene derivatives serve as the lead compounds for a novel type of antitumor agents.